3708 related articles for article (PubMed ID: 6539651)
1. Studies on drug resistance in a human melanoma xenograft system.
Osieka R
Cancer Treat Rev; 1984 Mar; 11 Suppl A():85-98. PubMed ID: 6539651
[TBL] [Abstract][Full Text] [Related]
2. Human malignant melanoma: preclinical and clinical drug evaluation.
Osieka R
Behring Inst Mitt; 1984 May; (74):353-67. PubMed ID: 6383327
[TBL] [Abstract][Full Text] [Related]
3. Primary and acquired resistance to antineoplastic chemotherapy. A preclinical and clinical study.
Osieka R
Cancer; 1984 Sep; 54(6 Suppl):1168-74. PubMed ID: 6380697
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
Budach W; Budach V; Stuschke M; Schmauder B; Reipke P; Scheulen ME
Br J Cancer; 1994 Jul; 70(1):29-34. PubMed ID: 8018537
[TBL] [Abstract][Full Text] [Related]
5. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
[TBL] [Abstract][Full Text] [Related]
6. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
7. Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
Didolkar MS; Baffi RR; Catane R; Kaufman J; Holyoke ED
Cancer Treat Rep; 1977 Dec; 61(9):1738-9. PubMed ID: 597824
[No Abstract] [Full Text] [Related]
8. Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts.
Dunn TA; Grünwald V; Bokemeyer C; Casper J
Invest New Drugs; 1997; 15(2):91-8. PubMed ID: 9220287
[TBL] [Abstract][Full Text] [Related]
9. Results with methyl-CCNU and DTIC in metastatic melanoma.
Costanza ME; Nathanson L; Schoenfeld D; Wolter J; Colsky J; Regelson W; Cunningham T; Sedransk N
Cancer; 1977 Sep; 40(3):1010-5. PubMed ID: 332319
[TBL] [Abstract][Full Text] [Related]
10. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma.
Becher R; Seeber S; Schmidt CG
J Cancer Res Clin Oncol; 1980; 97(3):301-6. PubMed ID: 7192287
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
[TBL] [Abstract][Full Text] [Related]
13. Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin.
Kjønniksen I; Breistøl K; Fodstad O
Cancer Res; 1992 Mar; 52(5):1347-51. PubMed ID: 1737396
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitization by chlorpromazine (CPZ) and caffeine (C) in human melanoma xenografts sensitive or resistant to methyl-CCNU (semustine).
Osieka R; Glatte P; Schmidt CG
Strahlenther Onkol; 1989 Jul; 165(7):526-8. PubMed ID: 2749491
[No Abstract] [Full Text] [Related]
15. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
Einhorn LH; Furnas B
Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
[TBL] [Abstract][Full Text] [Related]
16. Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase I-II trial.
Ringborg U; Jungnelius U; Hansson J; Strander H
Am J Clin Oncol; 1990 Jun; 13(3):214-7. PubMed ID: 2346126
[TBL] [Abstract][Full Text] [Related]
17. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
18. The usefulness of human tumor cell lines in the study of chemosensitivity. A study of malignant melanomas.
Tveit KM; Fodstad O; Pihl A
Int J Cancer; 1981 Oct; 28(4):403-8. PubMed ID: 7309286
[TBL] [Abstract][Full Text] [Related]
19. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
20. Emergence of nitrosourea resistant sublines of Lewis lung tumour following MeCCNU treatment in vivo.
Stephens TC; Adams K; Peacock JH
Br J Cancer; 1986 Feb; 53(2):237-45. PubMed ID: 3954945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
